The vaccine, known as rVSV-ZEBOV and developed by Merck (NYSE:MRK), is not yet licensed but was shown to be highly protective against Ebola in clinical trials published last December. Related stocks: JNJ, GSK, HEB, BCRX, NLNK, NNVC, INO, OTCQB:GOVX, SRPT, CMRX, PLX, NSPH, LAKE, APT, VSR, SMED Democratic Republic of Congo's health ministry has approved the use of a new Ebola vaccine to counter an outbreak of the hemorrhagic fever in its northeast that has killed four people.
An Ebola vaccine has been approved for use in DR Congo's outbreak — Quartz
On May 12, the World Health Organization declared an Ebola outbreak in DR Congo after it confirmed three deaths. Now, with as many as 52 suspected cases, DR Congo's health ministry is stepping up its response and has approved the use of a new experimental vaccine to stop the outbreak. DR Congo's relative containment of the virus so far has been attributed to the outbreak's occurrence in a remote part of the country's northeast. In its battle to stop the spread of the Ebola after a recent outbreak, a new WHO-backed vaccine is the Democratic Republic of Congo's weapon of choice. In a previous outbreak mainly in the West African countries of Liberia, Sierra Leone and Guinea, the Ebola virus killed over 11,000 people as health services were ill-prepared to respond to the outbreak.collected by :Lucy William
No comments:
Post a Comment